Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 29 recruiting now full pipeline

Chronic Obstructive Pulmonary Disease: full-pipeline trial registry

29 of 87 indexed Chronic Obstructive Pulmonary Disease trials are currently recruiting.

Corpus placement: #158 of 28,707 conditions by registered trial count.

87 US clinical trials · 29 currently recruiting · #158 of 28,707 conditions by registered trial count

Chronic Obstructive Pulmonary Disease: 87 US clinical trials tracked, 29 recruiting.

Chronic Obstructive Pulmonary Disease is the subject of 87 registered US clinical trials on ClinicalTrials.gov, 29 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 6 of these trials.

Enrollment posture brief

Registry condition chronic-obstructive-pulmonary-disease

OPEN 29 | RECR 33% | LATE 19 | EARLY 27 | RANK #158 | SPON 6

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Glioma54.5%Alcohol Drinking47.7%Chronic Obstructive Pulm (th…33%End Stage Renal Disease28.4%Osteoporosis12.6%
Open-enrollment share among volume-matched conditions near Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease lists 29 open slots (33% of 87 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chronic Obstructive Pulmonary Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chronic Obstructive Pulmonary Disease is recruiting below its size-band peers.

    29 of 87 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Chronic Obstructive Pulmonary Disease trials is spread across many organizations.

    Sanofi accounts for 6 of 87 trials (6.9%). 62 distinct sponsors appear on at least one study for this condition label.

  3. Typical Chronic Obstructive Pulmonary Disease enrolment sits around 136 participants.

    Median target enrolment is 136 among the 87 trials that report a genuine target (sentinel values excluded). 36 of those (41.4%) plan for fewer than 100 participants.

  4. Chronic Obstructive Pulmonary Disease research is mostly interventional.

    70 interventional and 17 observational studies make up this index (80.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 19Phase 218Phase 315Phase 44

Open and recent trials

87 total, page 2 of 2

COMPLETED Phase 3 440 participants

NVA237 Versus Placebo 12-week Efficacy Study

Novartis Pharmaceuticals

NCT01709864

COMPLETED Phase 3 357 participants

Efficacy and Safety Study of QVA149 in COPD Patients

Novartis Pharmaceuticals

NCT02487446

COMPLETED 336 participants

Audio Data Collection for Identification and Classification of Coughing

HealthMode

NCT04326309

COMPLETED 330 participants

HIV-related Accelerated Aging of the Airway Epithelium

Weill Medical College of Cornell University

NCT01974219

COMPLETED Phase 2 237 participants

PT003 MDI Cardiovascular Safety Study

Pearl Therapeutics

NCT01349803

COMPLETED NA 200 participants

Anxiety and COPD Evaluation

NYU Langone Health

NCT02740465

COMPLETED NA 182 participants

Active for Life: Chronic Obstructive Pulmonary Disease

University of Michigan

NCT03201198

COMPLETED NA 172 participants

Remote Physician Care for Home Hospital Patients

Brigham and Women's Hospital

NCT04080570

COMPLETED NA 142 participants

Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN (V-TRaIN)

University of Chicago

NCT02611531

COMPLETED NA 139 participants

Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA

Peter Lindenauer, MD

NCT05562037

COMPLETED Phase 2 118 participants

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Pearl Therapeutics

NCT01085045

COMPLETED 100 participants

Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease

University of North Carolina, Chapel Hill

NCT00903955

COMPLETED NA 97 participants

Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions

Treatment Research Institute

NCT02059005

COMPLETED NA 91 participants

Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD

New York Presbyterian Brooklyn Methodist Hospital

NCT03094806

COMPLETED 75 participants

Vibration Response Imaging in Chronic Obstructive Pulmonary Disease and Asthma

Deep Breeze

NCT00542282

COMPLETED Phase 4 70 participants

Nebulized Hypertonic Saline for Inpatient Use in COPD

OhioHealth

NCT02266875

COMPLETED Phase 3 68 participants

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Novartis Pharmaceuticals

NCT00622635

COMPLETED Phase 2 64 participants

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Mylan

NCT02109172

COMPLETED Phase 2 57 participants

Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

Chiesi Farmaceutici S.p.A.

NCT00640484

COMPLETED NA 56 participants

COPD Assessment and Management Bundle Versus Usual Care

University of Illinois at Chicago

NCT01833026

COMPLETED NA 52 participants

Indoor Air Quality and Respiratory Symptoms in Former Smokers

Intermountain Health Care

NCT02956213

COMPLETED Phase 2 46 participants

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

Verona Pharma

NCT06545500

COMPLETED Phase 2 33 participants

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

Verona Pharma

NCT07132983

COMPLETED 33 participants

Modifying Exercise for the COPD Patient

Angela N Fellner PhD CCRP

NCT02143206

COMPLETED Phase 1 26 participants

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

Kimera Society

NCT02216630

COMPLETED Phase 2 25 participants

A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00094562

COMPLETED Phase 2 24 participants

Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients

Louisiana State University Health Sciences Center in New Orleans

NCT01941225

COMPLETED Phase 1 20 participants

Mindfulness Based Stress Reduction in COPD

Mayo Clinic

NCT01058499

COMPLETED NA 20 participants

Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease

Dartmouth-Hitchcock Medical Center

NCT01391559

COMPLETED Phase 2 17 participants

Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies

University of Alabama at Birmingham

NCT03244059

COMPLETED NA 15 participants

Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease

Breathe Technologies

NCT01372462

COMPLETED Phase 1 15 participants

Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)

Mayo Clinic

NCT04047810

COMPLETED Phase 4 14 participants

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

NCT02845752

COMPLETED NA 12 participants

Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients

Texas A&M University

NCT01154400

COMPLETED Phase 1 11 participants

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Gilead Sciences

NCT02077465

COMPLETED NA 8 participants

Uphill Walking as Exercise for COPD Patients

VA Office of Research and Development

NCT04026529

COMPLETED NA 7 participants

Rural Home Hospital: Proof of Concept

Brigham and Women's Hospital

NCT04531280

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 18
Phase 3 15
Phase 4 4

Named interventions

Most-linked intervention names on Chronic Obstructive Pulmonary Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
19 trials
Formoterol Fumarate 12 μg (Foradil® Aerolizer®) Drug
2 trials
PT005 MDI Drug
2 trials
PT003 MDI Drug
2 trials
salmeterol Drug
2 trials
Inhaled Long-Acting Muscarinic Antagonist Drug
2 trials
Inhaled Long-Acting Beta Agonist Drug
2 trials
Inhaled Corticosteroid Drug
2 trials

US sites by state

Facility locations filed on Chronic Obstructive Pulmonary Disease trials. A trial with sites in several states counts in each.

Florida 28 trials
California 26 trials
Arizona 18 trials
Alabama 18 trials
North Carolina 14 trials
Colorado 14 trials
Pennsylvania 13 trials
Illinois 13 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chronic Obstructive Pulmonary Disease page

87 registered trials, 29 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 29 Chronic Obstructive Pulmonary Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Sanofi sponsors the most Chronic Obstructive Pulmonary Disease trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Obstructive Pulmonary Disease condition card totals 87 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.